Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
AssigneePierre Fabre Medicament
InventorsJoel Bougaret, Jean-Louis Avan, Roland Segonds
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs.
Claims8
A pharmaceutical composition comprising 5 to 25% of a salt of idazoxan, 10 to 40% of microcrystalline cellulose, 0.1 to 5% of lubricant, 0.1 to 0.5% of colloidal silica and 25% to 90% of lactose, with respect to the total mass;
- wherein said idazoxan is a polymorph of form VI having an X-Ray diffraction pattern comprising characteristic peaks at 5.6150, 6.7350, 7.5350, 9.5250, 10.3450, 10.6050, 11.0350, 11.2850, 11.5350, 12.1150, 12.3750, 12.9550, 13.5150, 13.9950, 14.5250, 14.9350, 15.0450, 15.1950, 16.3450, 17.0450, 17.2850, 17.5750 and 17.8250 degrees θ;
- and a differential thermal analysis thermogram exhibiting a single maximum value at approximately 208.1+1.0.
A polymorphic form VI of idazoxan wherein the X-Ray diffraction spectrum comprises characteristic peaks at 5.6150, 6.7350, 7.5350, 9.5250, 10.3450, 10.6050, 11.0350, 11.2850, 11.5350, 12.1150, 12.3750, 12.9550, 13.5150, 13.9950, 14.5250, 14.9350, 15.0450, 15.1950, 16.3450, 17.0450, 17.2850, 17.5750 and 17.8250 degrees θ;
- and the differential thermal analysis thermogram of the polymorph of form VI exhibits a single maximum value at approximately 208.1±1.0.
Dependencies are inferred from the claim text.